Development and validation of a resazurin assay for in vitro susceptibility testing of Actinomadura madurae: a common causative agent of actinomycetoma

Abstract Objectives Actinomycetoma is a chronic granulomatous disease affecting skin, subcutaneous tissue, fascia, muscle and bones. With increasing resistance against commonly used treatment regimens, susceptibility testing is urgently needed. Methods We developed an in vitro susceptibility assay f...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 2023-01, Vol.78 (1), p.155-160
Main Authors: Abd Algaffar, S O, Verbon, A, Khalid, S A, van de Sande, W W J
Format: Article
Language:English
Subjects:
Amikacin
Amoxicillin
Anti-Bacterial Agents - pharmacology
Anti-Bacterial Agents - therapeutic use
Ceftriaxone
Ciprofloxacin
Doxycycline
Humans
Ifosfamide
Imipenem
Linezolid - pharmacology
Microbial Sensitivity Tests
Mycetoma - drug therapy
Rifampin
Trimethoprim, Sulfamethoxazole Drug Combination
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objectives Actinomycetoma is a chronic granulomatous disease affecting skin, subcutaneous tissue, fascia, muscle and bones. With increasing resistance against commonly used treatment regimens, susceptibility testing is urgently needed. Methods We developed an in vitro susceptibility assay for Actinomadura madurae, one of the common causative agents of actinomycetoma, employing resazurin for endpoint reading. Using this assay, reproducible MICs were determined for the most commonly used antibacterial agents for actinomycetoma treatment. The tested antibacterial agents included trimethoprim/sulfamethoxazole, amikacin, streptomycin, amoxicillin, ceftriaxone, gentamicin, ciprofloxacin, doxycycline, imipenem, linezolid, penicillin G and rifampicin. Results Following the clinical breakpoints as stated by CLSI, 100% of the tested strains were susceptible to trimethoprim/sulfamethoxazole (MIC 0.03/0.59–1/19 mg/L), amikacin (MIC 0.0078–0.25 mg/L), doxycycline (MIC
ISSN:0305-7453
1460-2091
DOI:10.1093/jac/dkac367